Department of Pediatric, Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun 130021, China.
Department of Pediatric, Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun 130021, China.
Chin J Nat Med. 2019 Apr;17(4):252-263. doi: 10.1016/S1875-5364(19)30029-9.
Astragalus membranaceus may be a potential therapy for childhood asthma but its driving mechanism remains elusive. The main components of A. membranaceus were identified by HPLC. The children with asthma remission were divided into two combination group (control group, the combination of budesonide and terbutaline) and A. membranaceus group (treatment group, the combination of budesonide, terbutaline and A. membranaceus). The therapeutic results were compared between two groups after 3-month therapy. Porcine peripheral blood mononuclear cells (PBMCs) were isolated from venous blood by using density gradient centrifugation on percoll. The levels of FoxP3, EGF-β, IL-17 and IL-23 from PBMCs and serum IgE were measured. The relative percentage of Treg/Th17 cells was determined using flow cytometry. The main components of A. membranaceus were calycosin-7-O-glucoside, isoquercitrin, ononin, calycosin, quercetin, genistein, kaempferol, isorhamnetin and formononetin, all of which may contribute to asthma therapy. Lung function was significantly improved in the treatment group when compared with a control group (P < 0.05). The efficacy in preventing the occurrence of childhood asthma was higher in the treatment group than the control group (P < 0.05). The levels of IgE, IL-17 and IL-23 were reduced significantly in the treatment group when compared with the control group, while the levels of FoxP3 and TGF-β were increased in the treatment group when compared with the control group (P < 0.05). A. membranaceus increased the percentage of Treg cells and reduced the percentage of Th17 cells. A. membranaceus is potential natural product for improving the therapeutic efficacy of combination therapy of budesonide and terbutaline for the children with asthma remission by modulating the balance of Treg/Th17 cells.
黄芪可能是治疗儿童哮喘的一种潜在疗法，但它的作用机制仍不清楚。用高效液相色谱法鉴定黄芪的主要成分。将哮喘缓解的患儿分为两组联合治疗（对照组，布地奈德和特布他林联合治疗；治疗组，布地奈德、特布他林和黄芪联合治疗）。经过 3 个月的治疗后，比较两组的治疗效果。采用密度梯度离心法从猪外周血单个核细胞（PBMCs）中分离 PBMCs。用流式细胞术测定 PBMCs 和血清 IgE 中的 FoxP3、EGF-β、IL-17 和 IL-23 水平。用流式细胞术测定 Treg/Th17 细胞的相对比例。黄芪的主要成分有毛蕊异黄酮-7-O-葡萄糖苷、异槲皮苷、芒柄花素、毛蕊异黄酮、槲皮素、染料木素、山奈酚、异鼠李素和芒柄花苷，这些成分可能有助于哮喘的治疗。与对照组相比，治疗组的肺功能明显改善（P<0.05）。治疗组预防儿童哮喘发生的疗效高于对照组（P<0.05）。与对照组相比，治疗组 IgE、IL-17 和 IL-23 水平明显降低，而 FoxP3 和 TGF-β 水平明显升高（P<0.05）。黄芪增加了 Treg 细胞的比例，降低了 Th17 细胞的比例。黄芪可能是一种潜在的天然产物，通过调节 Treg/Th17 细胞的平衡，改善布地奈德和特布他林联合治疗儿童哮喘缓解的疗效。
